Dan Anderson is Eikon’s Chief Scientific Officer and leads all drug discovery functions at the Company.
Prior to joining Eikon, Dan was Vice President of Biology at Recursion Pharmaceuticals, a company industrializing phenotypic screening and utilizing machine learning to disrupt drug discovery. While at Recursion Dan oversaw platform technology advancements and discovery program validation.
Before joining Recursion Dan worked at Cleave Biosciences as Head of Biology where he contributed to various aspects of the p97 program from early screening efforts through clinical development.
Dan began his biotech career at Genentech where he led the group responsible for developing novel cellular and advanced microscopy assays to report on drug activity and mechanisms of action.
He earned his PhD in cell biology and biochemistry from the University of California, San Diego and has authored over 20 publications and four patents.